Skip to main content
VCbacked
Log inGet Started

LTZ Therapeutics

San Francisco, United States

LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.

$40.0M raised
May 2026
Venture - Series Unknown
BiotechnologyHealth CareMedical

Top Investors

Eli LillyQiming Venture PartnersShunwei CapitalLanchi Ventures5Y Capital

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about LTZ Therapeutics

How much funding has LTZ Therapeutics raised?
LTZ Therapeutics has raised $40.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2026.
Who are LTZ Therapeutics's investors?
LTZ Therapeutics's investors include Eli Lilly, Qiming Venture Partners, Shunwei Capital, Lanchi Ventures, 5Y Capital.
Where is LTZ Therapeutics headquartered?
LTZ Therapeutics is headquartered in San Francisco, United States.
What does LTZ Therapeutics do?
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
What stage is LTZ Therapeutics at?
LTZ Therapeutics is at the Venture - Series Unknown stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"LTZ Therapeutics — Funding & Investors." VCBacked, May 6, 2026, https://www.vcbacked.co/company/ltz-therapeutics. Accessed June 3, 2026.
APA
VCBacked. (2026). LTZ Therapeutics — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/ltz-therapeutics
Wikipedia (cite web)
{{cite web |title=LTZ Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ltz-therapeutics |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong